First Long-Term CLA Study Shows 9 Percent Reduction in Body Fat and 2 Percent Increase in Lean Muscle

Results showing TONALIN® CLA’s long-term efficacy to be presented
at AOCS Annual Meeting

LA GRANGE, IL, April 30, 2003 – Cognis, a global specialty chemicals and nutritional ingredients company, and exclusive manufacturer of TONALIN® brand conjugated linoleic acid (CLA), has announced that results from the first long-term CLA study demonstrate the most significant reduction in body fat and increase in lean muscle taking TONALIN® CLA. The study’s results will be presented at the American Oil and Chemist Society’s (AOCS) 94th Annual Meeting and Expo to be held in Kansas City, MI, May 4-7, 2003. The study results also will be conveyed to attendees of a Cognis-sponsored Vendorworks presentation at SupplySide East to be held in Secaucus, NJ, May 5-7, 2003.

While short-term CLA studies with short supplementation periods have shown that CLA use improves body composition, there have not yet been any studies on TONALIN® CLA’s long-term effects until now. Jean-Michel Gaullier’s “Efficacy and safety of one-year supplementation with conjugated linoleic acid in moderate overweight” demonstrated that TONALIN® CLA reduced body fat by nine percent and increased lean muscle by two percent. The most remarkable effects on body composition were produced by trials performed with a mixture of the bioactive isomers (cis-9, trans-11 and trans-10, cis-12). Specifically, TONALIN® CLA generated a significant decrease in body fat, body weight and body mass index.

Overweight subjects were randomized in three groups, and supplemented for one year either with CLA given as free fatty acid, or as triglycerides, and compared with a placebo (olive oil). Measurements performed with dual-energy X-ray absorptiometry show significant changes over time. Possible factors such as diet and training were also analyzed. In addition, the long-term safety of TONALIN® CLA was confirmed through rigorous recording of any side effects occurring during the overall study and analyses of blood parameters, including blood lipids and diabetes markers. Finally, records of the quality-of-life have been done in order to evaluate how TONALIN® CLA affected the daily life of the subjects included in the study.

According to Kathleen Moran, Market Segment Manager, Dietary Supplements, for Cognis Nutrition and Health, “We eagerly await the presentation of the first long-term CLA study results at AOCS’ 94th Annual Meeting and Expo, and at SupplySide East. Numerous studies utilizing TONALIN® CLA have consistently demonstrated its ability to reduce body fat in humans for improved overall body composition. Mr. Gaullier’s study is the first to examine CLA’s efficacy and effects long-term, and revealed the most significant body fat reduction and lean muscle mass increase to date. These results should further confirm the merits of TONALIN® CLA’s proprietary isomer profile to the industry and consumers alike.”

For more information on AOCS’ 94th Annual Meeting and Expo, please visit Additional details on SupplySide East are available at

TONALIN® CLA utilizes a new proprietary process that converts linoleic acid from safflower oil into CLA which provides the highest activity available at 80 percent. It is the brand used in most clinical research confirming CLA’s benefits for human health, including seven published studies on CLA in the past 18 months. In 2003, results from a 12 month clinical study will be published demonstrating a beneficial role for TONALIN® CLA in body weight management.

For information in North America about TONALIN® brand CLA, please call 800.673.3702 to place an order, e-mail [email protected], or fax 513.482.3576. For information in Europe about TONALIN® brand CLA, call +49.211.794.9692, e-mail [email protected], or fax +49.211.798.2390. For information in Asia Pacific about TONALIN® brand CLA, call +61.3.9584.4588.

About CLA:

CLA is a polyunsaturated, conjugated fatty acid that is a natural part of the human diet through its presence in meat and dairy products. The CLA content of natural dairy products has fallen over time, and the human body now needs to supplement its consumption of CLA from other sources. Natural has developed and patented a number of CLA-containing substances, and expects to see CLA used in the future for preventive medical purposes.

About Cognis:

Cognis is a worldwide supplier of innovative specialty chemicals and nutritional ingredients with almost 9,000 employees in close to 50 countries. The company has dedicated its activities to a high level of sustainability and delivers natural source raw materials and ingredients for food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Additionally, Cognis provides solutions for a number of other industries, such as coatings and inks, lubricants, textiles and plastics, as well as agro and mining.

Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and Schroder Ventures Life Sciences. In 2002, Cognis recorded sales of 3.1 billion euros and an operating profit before depreciation, amortization and exceptional items (EBITDA recurring) of 393 million euros.


Susanne Marell, Vice President Cognis Corporate Communications,
Cognis Deutschland GmbH & Co. KG

Phone: +49-211-7940-5395
e-mail: [email protected]

Susanne Sengel, Corporate Communications Manager,
Cognis Deutschland GmbH & Co. KG

Phone: +49-211-7940-5431
e-mail: [email protected]

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.